Current Research Status and Development Trends of Astragalus membranaceus Based on Visual Mapping Analysis with VOSviewer and CiteSpace

HU Lizhe; ZHANG Bo; HU Danling; DAI Xiaofeng; CHEN Jieyin; SUN Yongwei; KONG Zhiqiang

doi:10.11924/j.issn.1000-6850.casb2024-0658

PDF(2712 KB)

Chin Agric Sci Bull ›› 2025, Vol. 41 ›› Issue (14) : 137-148. DOI: 10.11924/j.issn.1000-6850.casb2024-0658

Current Research Status and Development Trends of Astragalus membranaceus Based on Visual Mapping Analysis with VOSviewer and CiteSpace

HU Lizhe ¹^,² ,
ZHANG Bo ¹^,³ ,
HU Danling ¹^,² ,
DAI Xiaofeng ¹ ,
CHEN Jieyin ¹ ,
SUN Yongwei ² ,
KONG Zhiqiang ¹

Author information +

History +

Abstract

Based on VOSviewer and CiteSpace, the research hotspots and trends in the field of Astragalus membranaceus research at domestic and international level were explored. Chinese and English literature on Astragalus membranaceus related studies published in the core collections of China National Knowledge Internet (CNKI), Wanfang, Vipshop(VIP) and Web of Science (WOS) from 2000 to 2023 were collected. VOSviewer was used to draw the author cooperation network and the scientific knowledge map of keyword co-occurrence network in Chinese and English literature, and CiteSpace was used to draw the publication journal, publication institution, keyword clustering, keyword timeline and keyword emergence map. A total of 8602 articles were included, including 8089 articles in Chinese and 513 articles in English. The authors with the highest number of publications in both Chinese and English are Qin Xuemei (Modern Research Center of Traditional Chinese Medicine, Shanxi University) and Liu Ping (Capital Medical University). Among the issuing institutions, Beijing University of Traditional Chinese Medicine tops the list in terms of the number of articles issued in Chinese, while Shanghai University of Traditional Chinese Medicine and Nanjing University of Traditional Chinese Medicine are the institutions with the highest number of articles issued in English. The English and Chinese journals with the largest number of articles on Astragalus membranaceus are Lishizhen Medicine and Materia Medica Research and Journal of Ethnopharmacology, respectively. Analysis of the keywords reveals that the main research direction of Astragalus focuses on the composition of Astragalus membranaceus, chemical composition, extraction process, mechanism of action, pharmacological effects, etc. Astragalus membranaceus annual publication volume shows a general trend of growth, with Beijing University of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Shanxi University Modern Research Centre of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine and Nanjing University of Traditional Chinese Medicine as the main colleges and universities, research institutions, researchers have carried out a large number of studies on Astragalus membranaceus. In recent years, the emergence of data mining, network pharmacology and molecular docking-based methods to reveal the pharmacological mechanisms of Astragalus membranaceus and classical formulas in disease resistance has become a research hotspot, in addition to the mechanism of action between Astragalus membranaceus actives and intestinal flora will be a research trend in the future research.

Key words

Astragalus membranaceus / VOSviewer / CiteSpace / visual analysis / hotspot analysis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HU Lizhe , ZHANG Bo , HU Danling , et al . Current Research Status and Development Trends of Astragalus membranaceus Based on Visual Mapping Analysis with VOSviewer and CiteSpace[J]. Chinese Agricultural Science Bulletin. 2025, 41(14): 137-148 https://doi.org/10.11924/j.issn.1000-6850.casb2024-0658

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	国家药典委员会. 中华人民共和国药典:一部[M]. 北京: 中国医药科技出版社, 2020:315-316. Cited in this article [1]

[2]	江远玲, 冯楠, 邵欣宇, 等. 黄芪的现代药理作用研究进展[J]. 西南医科大学学报, 2023, 46(5):456-460,463. Cited in this article [1]

[3]	李亮, 芦彩梅. 中药黄芪研究进展的CiteSpace知识图谱分析[J]. 山西大同大学学报(自然科学版), 2022, 38(3):63-68. Cited in this article [1]

[4]	鲍佳敏, 葛亮, 叶文芳. 黄芪研究热点:基于Citespace知识图谱分析[J]. 贵阳学院学报(自然科学版), 2023, 18(2):62-66,76. Cited in this article [1]

[5]

陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2):242-253.

Cited in this article [1] Abstract

科学知识图谱的概念和CiteSpace工具自引入国内学术界，就迅速得到了大量关注，相关文献犹如雨后春笋般见诸于国内各种情报学期刊。但我们通过阅读国内500多篇应用CiteSpace工具的论文，发现存在知识可视化工具“滥用”和“误用”的现象，这显示出学界对于该工具的方法论功能认识不足。本文从CiteSpace工具的设计理念、理论基础、使用流程和功能应用四个方面进行较为深入的阐释，以期国内学者能加深对该工具的理解，并能将其更有效地灵活应用于科学研究工作中。

[6]	范信晖, 李科, 杨一丹, 等. 黄芪多糖的结构表征研究进展[J]. 山西中医药大学学报, 2022, 23(3):260-267. Cited in this article [1]

[7]	范信晖, 李科, 杨一丹, 等. 黄芪多糖中抗炎组分的结构及其活性的初步研究[J]. 山西医科大学学报, 2021, 52(10):1346-1356. Cited in this article [1]

[8]	李科, 崔连杰, 李晓霞, 等. 黄芪活性多糖APS-Ⅱ酶解方法的建立及其降解寡糖的免疫活性研究[J]. 药学学报, 2021, 56(7):1936-1944. Cited in this article [1]

[9]	石丽霞, 李科, 焦思明, 等. 黄芪活性多糖APS-II的酸降解及其降解寡糖的结构和免疫活性研究[J]. 药学学报, 2021, 56(8):2266-2275. Cited in this article [1]

[10]	石丽霞, 李科, 秦雪梅. 黄芪多糖双向抗肿瘤作用机制的研究进展[J]. 山西中医药大学学报, 2021, 22(2):145-149. Cited in this article [1]

[11]	杨思霞, 李纬, 孙美花, 等. 含红芪、黄芪的益气养血汤与补中益气汤含药血清对SAMP8小鼠脾淋巴细胞免疫功能影响的比较研究[J]. 中国中西医结合杂志, 2019, 39(3):335-341. Cited in this article [1]

[12]	张高林, 程卫东, 张文君, 等. 比较含红芪和含黄芪的补中益气汤含药血清对SAMP8鼠脾淋巴细胞抗免疫老化的作用[J]. 中国中药杂志, 2016, 41(15):2888-2894. Cited in this article [1]

[13]	邢文婷, 张李峰, 程卫东, 等. 含红芪和含黄芪的补中益气汤含药血清对老龄小鼠脾淋巴细胞抗氧化损伤作用的比较[J]. 中药材, 2014, 37(2):299-302. Cited in this article [1]

[14]	杨筱倩, 丁煌, 刘晓丹, 等. 冰片配伍黄芪甲苷和三七总皂苷促进脑缺血再灌注后神经修复作用的研究[J]. 中华中医药杂志, 2019, 34(12):5854-5859. Cited in this article [1]

[15]	唐三, 丁煌, 杨筱倩, 等. 冰片配伍黄芪甲苷与三七总皂苷对脑缺血再灌注大鼠血脑屏障转运蛋白的影响[J]. 中草药, 2019, 50(18):4389-4397. Cited in this article [1]

[16]

, ZHENG

, BAI

, et al. Cycloastragenol reduced BBB disruption and ameliorated neuroinflammation of intracerebral hemorrhage in mice by modulating the p38 MAPK/Nrf2/HO-1 signaling pathway[J]. Journal of biological regulators and homeostatic agents, 2023, 37(10):5305-5318.

https://doi.org/10.23812/j.biol.regul.homeost.agents.20233710.513

Cited in this article [1] Abstract

Background: Intracerebral hemorrhage (ICH) is a prevalent cerebrovascular disorder in clinical practice. Secondary brain injury (SBI) is observed in the perihematomal tissue following ICH. A traditional Chinese herb astragalus membranaceus (AM) has been reported to treat cerebrovascular disease. The study aimed to explore the function and mechanism of cycloastragenol (CAG), a hydrolysis product of astragaloside IV isolated from AM, on ICH. Methods: Male Sprague-Dawley rats weighing 300 ± 20 g were randomly assigned to the sham group, ICH group, CAG-low group (CAG-L), CAG-medium group (CAG-M), and CAG-high group (CAG-H). Rats were used to establish an ICH model by intrastriatal injection of collagenase type IV. Different concentrations of CAG (2.5, 5, and 10 mg/kg) were intraperitoneally injected at 1 h and 6 h after immunohistochemistry (IHC) induction. Rats were necropsied on the 3 days after ICH induction. Neurobehavioral assessments (daily), blood-brain barrier (BBB) permeability, brain water content (BWC), immunofluorescence staining, and western blot were performed. HT22 cells were treated with different concentrations of CAG (1, 10, and 20 μM). Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8), while cell apoptosis was evaluated via flow cytometry. Results: CAG improves ICH-induced neurological deficits and neuronal apoptosis in a dose-dependent manner. CAG also decreases BBB permeability and BWC during continuous testing. Enzyme-linked immunosorbent assay (ELISA) of brain tissues from the peri-hematoma area shows CAG dose-dependently inhibited oxidative stress and inflammation of ICH rats. These functional improvements are correlated with reductions in inducible nitric oxide synthase (iNOS), interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α, and reactive oxygen species (ROS) levels as well as microglial deactivation. Mechanistically, CAG dose-dependently inhibits the p38 mitogen-activated protein kinase (MAPK)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling in neurons and astrocytes. In vitro, hemin induces apoptosis and inhibits proliferation of HT22 cells. In addition, CAG inhibits hemin-induced apoptosis and promotes proliferation of HT22 cells. Conclusions: Taken together, these data indicate that CAG may provide therapeutic benefits for ICH patients.

[17]	WEN D, TAN R Z, ZHAO C Y, et al. Astragalus mongholicus bunge and panax notoginseng (burkill) F.H. Chen formula for renal injury in diabetic nephropathy- in vivo and in vitro evidence for autophagy regulation[J]. Frontiers in pharmacology, 2020, 11:732. Cited in this article [1]

[18]	刘晓轩, 张驰, 黄思琪, 等. 黄精多糖类物质研究现状及发展动态的文献计量学分析[J]. 中草药, 2023, 54(21):7130-7141. Cited in this article [1]

[19]	陈惠玲, 王奇, 王建新, 等. 基于代谢的中药配伍减毒研究进展[J]. 环球中医药, 2023, 16(9):1920-1926. Cited in this article [1]

[20]	杨飞霞, 王玉, 夏鹏飞, 等. 当归补血汤化学成分、药理作用、临床应用的研究进展及质量标志物的预测分析[J]. 中国中药杂志, 2021, 46(11):2677-2685. Cited in this article [1]

[21]	HUANG X, GAO L W, DENG R Y, et al. Huangqi-Danshen decoction reshapes renal glucose metabolism profiles that delays chronic kidney disease progression[J]. Biomedicine & pharmacotherapy, 2023, 164:114989-114989. Cited in this article [1]

[22]	温芳, 舒鹏. 黄芪-党参药对治疗胃癌的网络药理学研究[J]. 中华中医药学刊, 2021, 39(2):89-94,267-268. Cited in this article [1]

[23]	WEI X M, CHEN X F, SHU P, et al. Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: a protocol for a randomized, controlled, double-blind, multicenter trial[J]. Medicine, 2020, 99(22):e19923. Cited in this article [1]

[24]	孟丹丹, 李宗新, 贾瑞雪, 等. 黄芪甲苷抗肿瘤作用机制研究进展[J]. 中草药, 2023, 54(3):1002-1009. Cited in this article [1]

[25]	TANG Z J, HUANG G L. Extraction, structure, and activity of polysaccharide from Radix astragali[J]. Biomedicine & pharmacotherapy, 2022, 150:113015-113015. Cited in this article [1]

[26]	牛明, 张斯琴, 张博, 等. 《网络药理学评价方法指南》解读[J]. 中草药, 2021, 52(14):4119-4129. Cited in this article [1]

[27]	ZHAO L, ZHANG H, LI N, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula[J]. Journal of ethnopharmacology, 2023, 309:116306-116306. Cited in this article [1]

[28]	HOPKINS A L. Network pharmacology[J]. Nature biotechnology, 2007, 25(10):1110-1111. https://doi.org/10.1038/nbt1007-1110 https://www.ncbi.nlm.nih.gov/pubmed/17921993 Cited in this article [1]

[29]	马思楠, 齐月. 基于网络药理学探讨黄芪-丹参治疗冠状动脉粥样硬化性心脏病作用机制[J]. 中医临床研究, 2024, 16(17):32-41. Cited in this article [1]

[30]	高风, 郭丽君, 张宏伟, 等. 基于VOSviewer和CiteSpace中医药领域细胞焦亡的知识图谱分析[J]. 中国中药杂志, 2023, 48(4):1098-1107. Cited in this article [1]

[31]	曾子玲, 佟琳, 刘思鸿, 等. 基于CiteSpace知识图谱的麦冬研究热点与趋势分析[J]. 中国中药杂志, 2021, 46(24):6549-6557. Cited in this article [1]

[32]	王成志, 刘一帆, 张晓青, 等. 黄芪甲苷调控免疫细胞抗肿瘤作用机制研究进展[J]. 中华中医药学刊, 2024, 42(11):145-149,289. Cited in this article [1]

[33]	周敏, 刘秀, 吴勇军, 等. 基于AMPK信号通路探讨黄芪甲苷对db/db小鼠2型糖尿病合并非酒精性脂肪肝病的作用机制[J]. 中国实验方剂学杂志, 2024, 30(5):72-79. Cited in this article [1]

[34]	李泓莹, 林煦垚, 史孟华, 等. 黄芪甲苷对小鼠TM3细胞凋亡的作用机制[J]. 中华中医药杂志, 2023, 38(5):2456-2459. Cited in this article [1]

[35]	ZHANG Y D, TAO C H, XUAN C, et al. Transcriptomic analysis reveals the protection of Astragaloside IV against diabetic nephropathy by modulating inflammation[J]. Oxidative medicine and cellular longevity, 2020:9542165. Cited in this article [1]

[36]	谭令, 龙霖梓, 邓秘, 等. 抗血小板活化的文献计量学及可视化分析[J]. 世界科学技术-中医药现代化, 2022, 24(1):195-208. Cited in this article [1]

[37]	和映玉, 邓清月, 李仙仙, 等. 基于VOSviewer和CiteSpace的菟丝子知识图谱可视化分析[J]. 中草药, 2023, 54(15):4958-4972. Cited in this article [1]

[38]	孙许宝, 韩清民. 黄芪注射液联合当归注射液对急性失血性休克患者围手术期血乳酸水平和氧代谢的影响[J]. 湖北中医学院学报, 2006(2):23-24. Cited in this article [1]

[39]	雷友富. 参麦、黄芪注射液联用治疗急性病毒性心肌炎疗效观察[J]. 中国现代医生, 2007(17):68. Cited in this article [1]

[40]	李淑萍, 许晓燕, 孙箴, 等. 黄芪多糖和黄芪总甙调控LX-2细胞因子分泌[J]. 浙江大学学报(医学版), 2007(6):543-548. Cited in this article [1]

[41]	韩冬. 黄芪甲苷对实验性糖尿病大鼠降糖、调脂和抗氧化作用的研究[J]. 现代中西医结合杂志, 2016, 25(4):360-364. Cited in this article [1]

[42]	段树卿, 李秀玲, 孙利, 等. 高效液相色谱法—蒸发光检测器测定复方石韦片中黄芪甲苷的含量[J]. 临床合理用药, 2024, 17(7):158-161. Cited in this article [1]

[43]	王祯, 张俊令, 焦宏基, 等. 黄芪有效成分的药理作用与质量控制研究进展[J]. 药物评价研究, 2023, 46(4):917-924. Cited in this article [1]

[44]	李欣, 杨闯, 吴文胜. 基于数据挖掘、网络药理学及分子对接的糖尿病性心脏病用药规律及核心中药分析[J]. 中医临床研究, 2024, 16(2):17-24. Cited in this article [1]

[45]	WANG J W, YAO M N, LI R L, et al. Network pharmacology-based prediction of active ingredient and mechanisms of Astragalus membranaceus and Panax notoginseng coupled-herbs against diabetic neuropathic pain[J]. Letters in drug design & discovery, 2023, 20(11):1830-1845. Cited in this article [1]

[46]	LI Z L, HU E, ZHENG F, et al. The effects of astragaloside IV on gut microbiota and serum metabolism in a mice model of intracerebral hemorrhage[J]. Phytomedicine, 2023, 121:155086-155086. Cited in this article [1]

[47]	KE M, SHEN Z, NING M, et al. Astragalus polysaccharides alleviates lipopolysaccharides-induced inflammatory lung injury by altering intestinal microbiota in mice[J]. Frontiers in microbiology, 2022, 13:1033875. Cited in this article [1]

[48]	宋沁洁, 李国峰, 李咸慰, 等. 黄芪药食同源现状分析[J]. 沈阳药科大学学报, 2023, 40(4):509-517. Cited in this article [1]

[49]	赵莉. 人参与4种中药配伍前后的质效评价研究[D]. 吉林: 吉林农业大学, 2016. Cited in this article [1]

[50]	向璐, 张巧艳, 赵琦明, 等. 黄芪-当归化学成分、药理作用及临床应用的研究进展[J]. 中草药, 2022, 53(7):2196-2213. Cited in this article [1]

[51]	刘俊, 于萧, 孔旋, 等. 丹参黄芪及其配伍对气虚血瘀大鼠模型微血管损伤的调节作用[J]. 陕西中医, 2017, 38(9):1311-1312. Cited in this article [1]

[52]	彭卫华, 曲强. 黄芪治疗肾脏疾病的现代药理研究[J]. 中国中西医结合肾病杂志, 2001(10):614-616. Cited in this article [1]

[53]	毕东雨, 范颖, 李洪洲, 等. 黄芪葛根汤与瓜蒌汤合方对糖尿病动脉粥样硬化大鼠主动脉SIRT1/AMPK信号通路的影响[J]. 中华中医药杂志, 2024, 39(2):951-956. Cited in this article [1]

[54]	李钦, 胡继宏, 高博, 等. 黄芪多糖在免疫调节方面的最新研究进展[J]. 中国实验方剂学杂志, 2017, 23(2):199-206. Cited in this article [1]

[55]	王荣, 孙艳平, 杨宽, 等. DPPH和T-AOC测定法评价黄芪桂枝配伍的抗氧化能力研究[J]. 中医药导报, 2018, 24(23):63-64,69. Cited in this article [1]

[56]

严毅超, 张露蓉. “黄芪-白术”药对在肝癌临床应用的组方规律及最适配伍比例[J]. 中国医院药学杂志, 2024, 44(10):1123-1131.

https://doi.org/10.13286/j.1001-5213.2024.10.03

Cited in this article [1] Abstract

目的探索临床应用于肝癌治疗的含“黄芪-白术”药对中药方剂的组方规律及最适配伍比例，为黄芪-白术在抗肝癌的临床合理应用提供证据。方法以中国知网、万方、维普数据库为来源，筛选符合条件处方，提取药物信息，建立数据汇总表。使用Excel 2019、SPSS Modeler 18.0、SPSS Statistics 24.0、中医传承辅助平台V2.50、RevMan 5.3统计软件进行组方分析和临床疗效评价；运用细胞增殖实验和肝癌小鼠生存期实验探讨黄芪-白术治疗肝癌的最佳比例。结果（1）黄芪-白术是治疗肝癌的常用药对。（2）组方分析显示与黄芪-白术药对配伍使用频次排名前5位的中药依次为茯苓、甘草、薏苡仁、麦芽、柴胡；药物类别以补虚药最多，其次是清热药、活血化瘀药和利水渗湿药。（3）Meta分析显示所有纳入文章偏倚不大，运用含黄芪-白术中药处方的治疗组，其对瘤体近期疗效的有效率显著高于对照组，OR=2.31，95%CI（1.80，2.97），P<0.000 1。（4）肝癌细胞增殖实验显示黄芪-白术比例为1∶1、2∶1、1∶2时IC50接近，分别为64.71、68.40、69.08 mg·mL–1；肝癌小鼠生存期实验显示黄芪-白术比例为1∶2时生存率最高，为62.5%，且抑瘤率最高，为35.97%。结论 “黄芪-白术”药对在肝癌临床治疗中应用广泛，黄芪-白术及其组方符合肝癌治疗的临床原则，具有良好的治疗作用；同时黄芪-白术比例为1∶2时，肝癌小鼠生存率最高，为临床合理组方配比提供依据。

[57]	郑文, 曹兰秀, 杜旭辉. 黄芪常用对药配伍机制研究进展[J]. 辽宁中医药大学学报, 2023, 25(10):205-209. Cited in this article [1]

[58]	郑雁雪, 王圆圆, 王琳, 等. 中药配伍减毒增效的现代研究及思考[J]. 中草药, 2023, 54(2):386-395. Cited in this article [1]

[59]	QIANBO S, WAN S C, DAN L, et al. Gut microbiota mediated hypoglycemic effect of Astragalus membranaceus polysaccharides in db/db mice[J]. Frontiers in pharmacology, 2022:1-14. Cited in this article [1]

[60]	袁伟琛, 甄建华, 李晓红. 黄芪抗肿瘤作用的研究现状[J]. 中华中医药学刊, 2023, 4(6):91-97. Cited in this article [1]

[61]	张瑞华, 张静文, 刘玲, 等. 黄芪及其有效组分药理作用与临床应用现状[J]. 陕西中医, 2021, 42(8):1138-1141,1146. Cited in this article [1]

[62]	刘燕, 蒋明琴, 李进杰. 黄芪茎叶提取物对仔猪生长性能、养分表观消化率及免疫指标的影响[J]. 中国饲料, 2024(4):41-44. Cited in this article [1]